Originally published by our sister publication Infectious Disease Special Edition
By Anna Tsioulias
The FDA approved the pneumococcal 21-valent conjugate vaccine (PCV21; Capvaxive, Merck) for adults to prevent against invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae. The vaccine has the potential to reduce the 150,000 hospitalizations and 41,000 deaths that occur as a result of pneumococcal pneumonia each year in the United States, according to the CDC.
The FDA based